Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B known ✓ | P28222 | 6/20 | 0.64 |
| ▸ | HTR1A known ✓ | P08908 | 3/20 | 0.64 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.64 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.64 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.64 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.64 |
| ▸ | HTR1D known ✓ | P28221 | 5/20 | 0.57 |
| ▸ | HTR1F known ✓ | P30939 | 2/20 | 0.56 |
| ▸ | HTR6 | P50406 | 16/20 | 0.65 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.64 |
| ▸ | DRD1 | P21728 | 1/20 | 0.64 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.64 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.64 |
| ▸ | HTR2A | P28223 | 2/20 | 0.56 |
| ▸ | HTR2C | P28335 | 2/20 | 0.56 |
| ▸ | HTR7 | P34969 | 2/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL505854 | 1.00 | HTR6 (0.65) | HTR6HTR1BHTR1ACHRM2ADRA2A | |
| Bromide SCHEMBL505856 | 1.00 | HTR6 (0.65) | HTR6HTR1BHTR1ACHRM2ADRA2A | |
| SCHEMBL505790 | 0.99 | HTR6 (0.66) | HTR6HTR1BHTR1ACHRM2ADRA2A | |
| SCHEMBL505789 | 0.99 | HTR6 (0.66) | HTR6HTR1BHTR1ACHRM2ADRA2A | |
| SCHEMBL505788 | 0.99 | HTR6 (0.66) | HTR6HTR1BHTR1ACHRM2ADRA2A | |
| SCHEMBL798333 | 0.99 | HTR6 (0.66) | HTR6HTR1BHTR1ACHRM2ADRA2A | |
| SCHEMBL10083480 | 0.99 | HTR6 (0.66) | HTR6HTR1BHTR1ACHRM2ADRA2A | |
| SCHEMBL1069045 | 0.96 | HTR6 (0.64) | HTR6HTR1BHTR1ACHRM2ADRA2A | |
| SCHEMBL1069044 | 0.96 | HTR6 (0.64) | HTR6HTR1BHTR1ACHRM2ADRA2A | |
| SCHEMBL1069043 | 0.96 | HTR6 (0.64) | HTR6HTR1BHTR1ACHRM2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071669-A1 | PROCESS FOR PREPARATION OF ELETRIPTAN AND SALT THEREOF | USV Limited B.S.D. Mar (IN) | 2012-03-22 | — | — | US | claimed |
| US-20120071669-A1 | PROCESS FOR PREPARATION OF ELETRIPTAN AND SALT THEREOF | USV Limited B.S.D. Mar (IN) | 2012-03-22 | — | — | US | disclosed |
| US-20120071669-A1 | PROCESS FOR PREPARATION OF ELETRIPTAN AND SALT THEREOF | USV Limited B.S.D. Mar (IN) | 2012-03-22 | — | — | US | disclosed |
| US-20120027816-A1 | HIGHLY PURE ELETRIPTAN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF ELETRIPTAN N-OXIDE IMPURITY | ACTAVIS GROUP PTC EHF (IS) | 2012-02-02 | — | — | US | disclosed |
| WO-2010097703-A1 | HIGHLY PURE ELETRIPTAN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF ELETRIPTAN N-OXIDE IMPURITY | ACTAVIS GROUP PTC EHF (IS) | 2010-09-02 | — | — | WO | disclosed |
| EP-0592438-B1 | INDOLE DERIVATIVES | PFIZER (US) | 1997-08-27 | — | — | EP | disclosed |
| US-5607951-A | SEROTONIN AGONIST FOR NERVOUS SYSTEM DISORDERS, ANALGESICS AND PSYCHOTHERAPEUTICS | PFIZER INC (US) | 1997-03-04 | — | — | US | disclosed |
| US-5578612-A | Indole derivatives | PFIZER INC. (US) | 1996-11-26 | — | — | US | disclosed |
| US-5559246-A | PROCESS OF DEHYDROHALOGENATION FOR CYCLIZATION TO PRODUCE PSYCHOTHERAPEUTIC AGENTS AND ANTISEROTONIN ANTAGONIST | PFIZER INC. (US) | 1996-09-24 | — | — | US | disclosed |
| US-5559129-A | SEROTONIN (5HT1) ANTAGONIST FOR TREATMENT OF DEPRESSION, ANXIETY, EATING DISORDERS, OBESITY, DRUG ABUSE, HEADACHES, AND PAIN | PFIZER INC (US) | 1996-09-24 | — | — | US | disclosed |
| US-5545644-A | SEROTONIN AGONISTS; HYPOTENSIVE AND ANXIOLYTIC AGENTS; ANALGESICS; ANTIDEPRESSANTS; EATING DISORDERS; DRUG ABUSE; HEADACHES; VASCULAR DISORDERS | PFIZER INC. (US) | 1996-08-13 | — | — | US | disclosed |
| WO-1992006973-A1 | INDOLE DERIVATIVES | PFIZER INC. (US) | 1992-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071669-A1 | PROCESS FOR PREPARATION OF ELETRIPTAN AND SALT THEREOF | HTR3C, SLC6A4, HTR3A | HTR1B 21/4885HTR1A 12/4885CHRM2 1355/4885 |
| US-20120027816-A1 | HIGHLY PURE ELETRIPTAN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF ELETRIPTAN N-OXIDE IMPURITY | SLC6A4, TPSD1, INMT | HTR1B 274/4885HTR1A 42/4885CHRM2 2858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.